Trump to visit Fed on Thursday amid Powell feud, renovation probe
Investing.com -- French pharmaceutical company Sanofi (NASDAQ:SNY) has agreed to purchase UK-based vaccine developer Vicebio in a deal worth up to $1.6 billion, adding new respiratory vaccine candidates to its pipeline.
The acquisition, announced Tuesday, includes an upfront payment of $1.15 billion with potential additional payments of up to $450 million tied to achieving specific development and regulatory milestones.
Through this purchase, Sanofi aims to strengthen its respiratory vaccines portfolio by acquiring two early-stage vaccine candidates targeting respiratory syncytial virus and human metapneumovirus. The deal also gives Sanofi access to Vicebio’s molecular clamp technology, which helps the immune system better recognize and respond to viral proteins.
The transaction is expected to be completed in the fourth quarter, pending customary closing conditions. Sanofi stated that the acquisition will not significantly impact its full-year financial guidance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.